Difference between revisions of "Stop-dosulepine"

From Psychiatrienet
Jump to: navigation, search
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
 
{{Drugswitch
 
{{Drugswitch
| from = Dosulepin
+
| from = dosulepin
| stop = {{StopAlgemeen}}
+
| stop = {{StopAlgemeen}}{{refBazire}}
 
{{ReduceMedication|dosulepin|150|100|75|50|25}}
 
{{ReduceMedication|dosulepin|150|100|75|50|25}}
 
}}
 
}}

Latest revision as of 16:41, 10 January 2013

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin


Nietinrijdenbord.png Stop dosulepin
  • In general after long-term maintenance treatment, the best is to reduce the dose by about 25% every 4-6 weeks. An apt pharmaceutical dose (tablet, capsule, mixture) is not always available. In these cases one should be creative with dosing.[1][2]
  • Another, more risky, possibility is being at a certain dose to use the following scheme:[3]
  • 150 mg/day:
  • Day 1: reduce dosage of dosulepin to 100 mg/day.
  • Day 8: reduce dosage of dosulepin to 75 mg/day.
  • Day 15: reduce dosage of dosulepin to 50 mg/day.
  • Day 22: reduce dosage of dosulepin to 25 mg/day.
  • Day 29 stop the administration of dosulepin.



  1. The UK Drug and Therapeutics Bulletin; 1999;37:49-52
  2. Editor: please note that not all dosages are available in pharmacy. So now and then you should be creative.
  3. Bazire S, Psychotropic Drug Directory 2010. Aberdeen: HealthComm UK Ltd; 2010.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.